MCID: LNG064
MIFTS: 62

Lung Cancer Susceptibility 3 malady

Categories: Rare diseases, Cancer diseases, Respiratory diseases, Genetic diseases

Aliases & Classifications for Lung Cancer Susceptibility 3

Aliases & Descriptions for Lung Cancer Susceptibility 3:

Name: Lung Cancer Susceptibility 3 54 13 69
Adenocarcinoma of Lung 12 29 42 69
Lung Adenocarcinoma 38 12 50 14
Non-Small Cell Adenocarcinoma 69
Nonsmall Cell Adenocarcinoma 12
Adenocarcinoma Lung 52

Classifications:



External Ids:

OMIM 54 612571
Disease Ontology 12 DOID:3910
MeSH 42 C538231
NCIt 47 C27745 C3512
SNOMED-CT 64 254626006

Summaries for Lung Cancer Susceptibility 3

NIH Rare Diseases : 50 lung adenocarcinoma is a cancer that occurs due to abnormal and uncontrolled cell growth in the lungs. it is a subtype of non-small cell lung cancer that is often diagnosed in an outer area of the lung. early lung cancers may not be associated with any signs and symptoms. as the condition progresses, affected people can experience chest pain, a persistent cough, fatigue, coughing up blood, loss of appetite, unexplained weight loss, shortness of breath, and/or wheezing. the underlying cause of lung adenocarcinoma is generally unknown; however, risk factors for developing a lung cancer include smoking; exposure to secondhand smoke and other toxic chemicals; a family history of lung cancer; previous radiation treatment to the chest or breast; and hiv infection. treatment varies based on the severity of the condition, the associated signs and symptoms and the affected person's overall health. it may include a combination of surgery, radiation therapy, chemotherapy, targeted therapy, and/or watchful waiting. last updated: 2/10/2016

MalaCards based summary : Lung Cancer Susceptibility 3, also known as adenocarcinoma of lung, is related to interstitial lung disease and marginal zone b-cell lymphoma. An important gene associated with Lung Cancer Susceptibility 3 is LNCR3 (Lung Cancer Susceptibility 3), and among its related pathways/superpathways are Developmental Biology and Cytokine Signaling in Immune system. The drugs Gilotrif and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and testes, and related phenotypes are Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance and Decreased viability with paclitaxel

Disease Ontology : 12 A non-small cell lung carcinoma that derives from epithelial cells of glandular origin.

Wikipedia : 71 Lung cancer susceptibility 3 is a protein that in humans is encoded by the LNCR3... more...

Description from OMIM: 612571

Related Diseases for Lung Cancer Susceptibility 3

Diseases in the Lung Cancer Susceptibility 3 family:

Lung Cancer Susceptibility 5 Lung Cancer Susceptibility 4
Lung Cancer Susceptibility 2

Diseases related to Lung Cancer Susceptibility 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 318)
id Related Disease Score Top Affiliating Genes
1 interstitial lung disease 30.0 EGFR TP53 VEGFA
2 marginal zone b-cell lymphoma 29.6 EGFR MMP2 TP53 VEGFA
3 peritoneal mesothelioma 29.6 CDH1 HRAS KRAS NKX2-1 TP53
4 colorectal cancer 28.8 CASP3 CDH1 CEACAM5 EGFR ERBB2 HRAS
5 bronchogenic lung adenocarcinoma 11.8
6 adenocarcinoma 11.1
7 tumor predisposition syndrome 10.9
8 lung papillary adenocarcinoma 10.8
9 severe pre-eclampsia 10.4 EGFR HRAS KRAS
10 ureter adenocarcinoma 10.4 EGFR KRAS NKX2-1
11 bile duct disease 10.4 EGFR HRAS KRAS
12 bone deterioration disease 10.4 KRAS NKX2-1 TP53
13 ovarian embryonal carcinoma 10.4 EGFR NKX2-1 TP53
14 pineal region mature teratoma 10.4 EGFR ERBB2
15 breast pericanalicular fibroadenoma 10.4 KRT20 NKX2-1 TP53
16 ossifying fibromyxoid tumor 10.4 HRAS KRAS TP53
17 pelvic inflammatory disease 10.4 HRAS KRAS KRT20
18 malignant skin fibrous histiocytoma 10.4 CEACAM5 HRAS KRAS
19 reactive arthritis 10.4 EGFR ERBB2 TP53
20 combined t cell and b cell immunodeficiency 10.4 CDH1 EGFR ERBB2
21 ovarian cystadenocarcinoma 10.4 EGFR ERBB2 VEGFA
22 aicardi-goutieres syndrome 10.4 HRAS KRAS TP53
23 giant cell tumor 10.4 KRAS KRT20 TP53
24 kidney clear cell sarcoma 10.4 EGFR HRAS KRAS NKX2-1
25 linitis plastica 10.4 CDH1 TP53
26 exudative glomerulonephritis 10.4 EGFR KRAS NKX2-1 TP53
27 spastic paraplegia 1 10.4 EGFR TP53 VEGFA
28 skin sarcoma 10.4 CEACAM5 EGFR ERBB2
29 pancreatic agenesis 10.4 EGFR KRT20 NKX2-1
30 nervous system hibernoma 10.4 EGFR ERBB2 KRT7
31 wolffian adnexal neoplasm 10.3 EGFR TP53
32 myxedema 10.3 EGFR HRAS KRAS TP53
33 striated muscle rhabdoid tumor 10.3 HRAS KRAS MMP2
34 spongiotic dermatitis 10.3 EGFR ERBB2 HRAS KRAS
35 vascular hemostatic disease 10.3 EGFR ERBB2 HRAS KRAS
36 retroperitoneal neuroblastoma 10.3 KRAS NAPSA TP53
37 spasmodic dysphonia 10.3 KRT20 KRT7 NKX2-1
38 nemaline myopathy 8, autosomal recessive 10.3 CDH1 ERBB2 KRAS
39 spastic diplegia infantile type 10.3 EGFR ERBB2 KRAS
40 peritoneal benign neoplasm 10.3 KRT20 KRT7 STK11
41 dystonia 10.3 KRT20 KRT7 STK11
42 anal canal paget's disease 10.3 KRT20 KRT7 STK11
43 pancreatic cystadenoma 10.3 EGFR KRAS NAPSA TP53
44 sclerosing hemangioma 10.3 CDH1 EGFR ERBB2
45 arthus reaction 10.3 ERBB2 HRAS KRAS TP53
46 retinal disease 10.3 CDH1 EGFR ERBB2
47 cervical serous adenocarcinoma 10.3 CEACAM5 HRAS KRAS
48 anus adenocarcinoma 10.3 EGFR ERBB2 KRT20
49 breast mucinous cystadenocarcinoma 10.3 CEACAM5 HRAS KRAS
50 bilateral hypoactive labyrinth 10.3 HRAS KRAS KRT7

Graphical network of the top 20 diseases related to Lung Cancer Susceptibility 3:



Diseases related to Lung Cancer Susceptibility 3

Symptoms & Phenotypes for Lung Cancer Susceptibility 3

Clinical features from OMIM:

612571

GenomeRNAi Phenotypes related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.35 HRAS STK11 VEGFA EGFR ERBB2
2 Decreased viability with paclitaxel GR00179-A-1 8.92 CASP3 EGFR ERBB2
3 Decreased viability with paclitaxel GR00179-A-3 8.92 EGFR

MGI Mouse Phenotypes related to Lung Cancer Susceptibility 3:

44 (show all 18)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.37 CASP3 CDH1 EGFR ERBB2 HRAS KRAS
2 cardiovascular system MP:0005385 10.35 CASP3 CDH1 EGFR ERBB2 HRAS KRAS
3 cellular MP:0005384 10.35 RASSF1 STK11 TP53 VEGFA CASP3 CDH1
4 mortality/aging MP:0010768 10.29 CASP3 CDH1 EGFR ERBB2 HRAS KRAS
5 endocrine/exocrine gland MP:0005379 10.28 CASP3 CDH1 EGFR ERBB2 HRAS KRAS
6 digestive/alimentary MP:0005381 10.25 CASP3 CDH1 EGFR ERBB2 KRAS NKX2-1
7 craniofacial MP:0005382 10.21 CASP3 EGFR ERBB2 HRAS KRAS MMP2
8 neoplasm MP:0002006 10.21 NKX2-1 OGG1 RASSF1 STK11 TP53 VEGFA
9 integument MP:0010771 10.16 CASP3 CDH1 EGFR ERBB2 HRAS KRAS
10 nervous system MP:0003631 10.14 TP53 VEGFA NKX2-1 OGG1 STK11 CASP3
11 normal MP:0002873 10.13 CDH1 EGFR ERBB2 HRAS KRAS MMP2
12 muscle MP:0005369 10.06 VEGFA CASP3 EGFR ERBB2 KRAS MMP2
13 liver/biliary system MP:0005370 10.04 EGFR KRAS OGG1 RASSF1 STK11 TP53
14 no phenotypic analysis MP:0003012 10.02 EGFR HRAS KRAS NKX2-1 STK11 TP53
15 renal/urinary system MP:0005367 9.86 CASP3 EGFR HRAS KRAS KRT7 STK11
16 reproductive system MP:0005389 9.81 CASP3 CDH1 EGFR ERBB2 KRAS NKX2-1
17 respiratory system MP:0005388 9.65 CASP3 EGFR ERBB2 HRAS KRAS MMP2
18 skeleton MP:0005390 9.28 CASP3 EGFR ERBB2 HRAS KRAS MMP2

Drugs & Therapeutics for Lung Cancer Susceptibility 3

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Gilotrif 17 46 AFATINIB DIMALEATE Boehringer Ingelheim Approved July 2013

Drugs for Lung Cancer Susceptibility 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 459)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33069-62-4 36314
2
Cisplatin Approved Phase 4,Phase 2,Phase 3,Phase 1 15663-27-1 84093 441203 2767
3
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
4
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
5
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 184475-35-2 123631
6
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 22916-47-8 4189
7
Everolimus Approved Phase 4,Phase 3,Phase 1,Phase 2 159351-69-6 6442177
8
Sunitinib Approved, Investigational Phase 4,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
9
Menthol Approved Phase 4 2216-51-5 16666
10
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
11
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 53123-88-9 5284616 6436030 46835353
12
Nicotine Approved Phase 4 54-11-5 942 89594
13
Midazolam Approved, Illicit Phase 4,Phase 1 59467-70-8 4192
14
Ribavirin Approved Phase 4 36791-04-5 37542
15
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
16
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
18
Caffeine Approved, Nutraceutical Phase 4 58-08-2 2519
19
Docetaxel Approved May 1996, Investigational Phase 4,Phase 2,Phase 3,Phase 1 114977-28-5 148124 9877265
20 pancreatic polypeptide Phase 4,Phase 2,Phase 3,Phase 1
21
Erlotinib Hydrochloride Phase 4,Phase 3,Phase 2,Phase 1 183319-69-9 176871
22 interferons Phase 4,Phase 2,Phase 1
23 Mitogens Phase 4,Phase 3,Phase 2,Phase 1
24 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1
25 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
26 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
27 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
28 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1
29 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1
30 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Phase 1
31 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1
32 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1
33 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
34 Antifungal Agents Phase 4,Phase 3,Phase 1,Phase 2
35 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
36 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1
37 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
38 Antimetabolites, Antineoplastic Phase 4,Phase 2,Phase 3,Phase 1
39 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
41 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Cholinergic Agents Phase 4
43 Adjuvants, Anesthesia Phase 4,Phase 3,Phase 1
44 GABA Agents Phase 4,Phase 1
45 GABA Modulators Phase 4,Phase 1
46 Neurotransmitter Agents Phase 4,Phase 2,Phase 1,Early Phase 1
47 Nicotinic Agonists Phase 4
48 Tranquilizing Agents Phase 4,Phase 2,Phase 1
49 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1
50 Anesthetics, General Phase 4,Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 844)
id Name Status NCT ID Phase
1 Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
2 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
3 A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations Completed NCT01609543 Phase 4
4 RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation Completed NCT01317615 Phase 4
5 Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Completed NCT01402089 Phase 4
6 Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma Completed NCT00630084 Phase 4
7 Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced Neuroendocrine Tumors Completed NCT01595009 Phase 4
8 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4
9 Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma Recruiting NCT02804646 Phase 4
10 Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma Recruiting NCT02103257 Phase 4
11 Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma Recruiting NCT01665417 Phase 4
12 Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Recruiting NCT02031601 Phase 4
13 Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation Active, not recruiting NCT02283424 Phase 4
14 Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC Active, not recruiting NCT02194556 Phase 4
15 Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly Active, not recruiting NCT02151149 Phase 4
16 Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma Not yet recruiting NCT02399566 Phase 4
17 Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Terminated NCT00536107 Phase 4
18 Pemetrexed (ALIMTA) and Gefitinib (IRESSA®) in Never-Smoker and Adenocarcinoma Patients With Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy Unknown status NCT01066195 Phase 3
19 Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT00955695 Phase 3
20 Effect of Astragalus-based Formula: Qingshu-Yiqi-Tang on Modulating Immune Alterations in Lung Cancer Patients Unknown status NCT01802021 Phase 2, Phase 3
21 Study of Ablation for the Pulmonary Focal Pure Ground Glass Opacity (pGGO) Unknown status NCT01429649 Phase 3
22 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3
23 Optimizing Dosing Regimen of Piperacillin/Tazobactam for Nosocomial Pneumonia Unknown status NCT01796717 Phase 2, Phase 3
24 First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker Completed NCT00455936 Phase 3
25 Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin Completed NCT00966914 Phase 3
26 BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation Completed NCT00949650 Phase 3
27 ADAM-Afatinib Diarrhea Assessment and Management Completed NCT01814553 Phase 3
28 Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer Completed NCT01404260 Phase 3
29 Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery Completed NCT00003387 Phase 3
30 Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00005838 Phase 3
31 Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer Completed NCT00002852 Phase 3
32 Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00020709 Phase 3
33 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Completed NCT00021060 Phase 2, Phase 3
34 Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer Completed NCT00002550 Phase 3
35 Lymph Node Removal in Treating Patients With Stage I or Stage II Non-small Cell Lung Cancer Completed NCT00003831 Phase 3
36 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Can Not Be Surgically Removed Completed NCT00003235 Phase 3
37 Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery Completed NCT00049543 Phase 3
38 Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00079287 Phase 3
39 Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer Completed NCT00002623 Phase 3
40 Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer Completed NCT00028938 Phase 3
41 Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Completed NCT00006484 Phase 3
42 Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery Completed NCT00003901 Phase 3
43 Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer Completed NCT00002823 Phase 3
44 Radiation Therapy to Relieve Symptoms in Patients With Non-small Cell Lung Cancer Completed NCT00003685 Phase 3
45 Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer Completed NCT00003117 Phase 3
46 An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation Completed NCT00132704 Phase 3
47 ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures Completed NCT00404924 Phase 3
48 Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis Completed NCT00243685 Phase 2, Phase 3
49 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3
50 Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer Completed NCT00056446 Phase 3

Search NIH Clinical Center for Lung Cancer Susceptibility 3

Cochrane evidence based reviews: adenocarcinoma of lung

Genetic Tests for Lung Cancer Susceptibility 3

Genetic tests related to Lung Cancer Susceptibility 3:

id Genetic test Affiliating Genes
1 Adenocarcinoma of Lung 29
2 Lung Adenocarcinoma 29

Anatomical Context for Lung Cancer Susceptibility 3

MalaCards organs/tissues related to Lung Cancer Susceptibility 3:

39
Lung, Breast, Testes, Endothelial, Adipocyte

Publications for Lung Cancer Susceptibility 3

Variations for Lung Cancer Susceptibility 3

ClinVar genetic disease variations for Lung Cancer Susceptibility 3:

6 (show top 50) (show all 110)
id Gene Variation Type Significance SNP ID Assembly Location
1 PRKN NM_013988.2(PARK2): c.(8_8)_(171_171)+180544del deletion Pathogenic GRCh38 Chromosome 6, 162262766: 162727661
2 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic/Likely pathogenic rs80338963 GRCh37 Chromosome 18, 48591918: 48591918
3 SMAD4 NM_005359.5(SMAD4): c.1157G> A (p.Gly386Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912580 GRCh37 Chromosome 18, 48593406: 48593406
4 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
5 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
6 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
7 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
8 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
9 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Pathogenic/Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
10 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
11 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
12 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
13 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
14 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
15 KRAS NM_033360.3(KRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
16 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
17 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
18 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
19 HRAS NM_005343.3(HRAS): c.436G> A (p.Ala146Thr) single nucleotide variant Pathogenic/Likely pathogenic rs104894231 GRCh37 Chromosome 11, 533467: 533467
20 HRAS NM_005343.3(HRAS): c.437C> T (p.Ala146Val) single nucleotide variant Pathogenic/Likely pathogenic rs121917759 GRCh37 Chromosome 11, 533466: 533466
21 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
22 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
23 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
24 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
25 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
26 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
27 ERBB2 NM_001005862.2(ERBB2): c.2223_2234dupATACGTGATGGC (p.Ala745_Gly746insTyrValMetAla) duplication Pathogenic/Likely pathogenic rs397516975 GRCh37 Chromosome 17, 37880984: 37880995
28 ERBB2 NM_004448.3(ERBB2): c.2328_2336dupTGTGGGCTC (p.Ser779_Pro780insValGlySer) duplication Pathogenic rs587776805 GRCh37 Chromosome 17, 37880999: 37881007
29 ERBB2 NM_001005862.2(ERBB2): c.2173_2174delTTinsCC (p.Leu725Pro) indel Pathogenic/Likely pathogenic rs121913469 GRCh37 Chromosome 17, 37880219: 37880220
30 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
31 RAF1 NM_002880.3(RAF1): c.770C> T (p.Ser257Leu) single nucleotide variant Pathogenic/Likely pathogenic rs80338796 GRCh37 Chromosome 3, 12645699: 12645699
32 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic/Likely pathogenic rs113488022 GRCh37 Chromosome 7, 140453136: 140453136
33 BRAF NM_004333.4(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913364 GRCh37 Chromosome 7, 140453134: 140453134
34 BRAF NM_004333.4(BRAF): c.1397G> T (p.Gly466Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913351 GRCh37 Chromosome 7, 140481411: 140481411
35 BRAF NM_004333.4(BRAF): c.1790T> G (p.Leu597Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913366 GRCh37 Chromosome 7, 140453145: 140453145
36 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913357 GRCh37 Chromosome 7, 140481403: 140481403
37 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
38 BRAF NM_004333.4(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913338 GRCh37 Chromosome 7, 140453154: 140453154
39 BRAF NM_004333.4(BRAF): c.1406G> A (p.Gly469Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
40 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh37 Chromosome 14, 105246551: 105246551
41 GNAS NM_000516.5(GNAS): c.601C> T (p.Arg201Cys) single nucleotide variant Pathogenic/Likely pathogenic rs11554273 GRCh37 Chromosome 20, 57484420: 57484420
42 GNAS NM_000516.5(GNAS): c.602G> A (p.Arg201His) single nucleotide variant Pathogenic/Likely pathogenic rs121913495 GRCh37 Chromosome 20, 57484421: 57484421
43 FGFR3 NM_000142.4(FGFR3): c.742C> T (p.Arg248Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913482 GRCh37 Chromosome 4, 1803564: 1803564
44 EGFR NM_005228.4(EGFR): c.2573T> G (p.Leu858Arg) single nucleotide variant drug response rs121434568 GRCh37 Chromosome 7, 55259515: 55259515
45 EGFR NM_005228.4(EGFR): c.2155G> T (p.Gly719Cys) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs28929495 GRCh37 Chromosome 7, 55241707: 55241707
46 CDK4 NM_000075.3(CDK4): c.70C> T (p.Arg24Cys) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs11547328 GRCh37 Chromosome 12, 58145431: 58145431
47 CTNNB1 NM_001904.3(CTNNB1): c.98C> A (p.Ser33Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh37 Chromosome 3, 41266101: 41266101
48 CTNNB1 NM_001904.3(CTNNB1): c.110C> G (p.Ser37Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 GRCh37 Chromosome 3, 41266113: 41266113
49 CTNNB1 NM_001904.3(CTNNB1): c.98C> T (p.Ser33Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh37 Chromosome 3, 41266101: 41266101
50 CTNNB1 NM_001904.3(CTNNB1): c.101G> A (p.Gly34Glu) single nucleotide variant Pathogenic/Likely pathogenic rs28931589 GRCh37 Chromosome 3, 41266104: 41266104

Cosmic variations for Lung Cancer Susceptibility 3:

9 (show top 50) (show all 1777)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM48853 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.622C>T p.R208C 16
2 COSM48854 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.128A>G p.N43S 16
3 COSM95558 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 16
4 COSM48850 ZAP70 lung,NS,carcinoma,adenocarcinoma c.1484C>T p.A495V 16
5 COSM95551 YWHAE lung,NS,carcinoma,adenocarcinoma c.146A>G p.Y49C 16
6 COSM49006 YES1 lung,NS,carcinoma,adenocarcinoma c.371+1G>T p.? 16
7 COSM48846 YES1 lung,NS,carcinoma,adenocarcinoma c.473G>T p.W158L 16
8 COSM94103 YBX3 lung,NS,carcinoma,adenocarcinoma c.655G>C p.A219P 16
9 COSM95540 WWP2 lung,NS,carcinoma,adenocarcinoma c.2280G>T p.W760C 16
10 COSM95537 WWP1 lung,NS,carcinoma,adenocarcinoma c.2098G>A p.D700N 16
11 COSM48844 WT1 lung,NS,carcinoma,adenocarcinoma c.668G>C p.S223T 16
12 COSM96290 WNT3 lung,NS,carcinoma,adenocarcinoma c.159C>A p.P53P 16
13 COSM96287 WNT16 lung,NS,carcinoma,adenocarcinoma c.156G>T p.L52L 16
14 COSM95520 WNT10A lung,NS,carcinoma,adenocarcinoma c.217G>A p.E73K 16
15 COSM95518 WNK2 lung,NS,carcinoma,adenocarcinoma c.1349C>A p.A450E 16
16 COSM95689 WNK1 lung,NS,carcinoma,adenocarcinoma c.3218C>G p.S1073* 16
17 COSM5369853 VHL lung,NS,carcinoma,adenocarcinoma c.514C>T p.P172S 16
18 COSM17658 VHL lung,NS,carcinoma,adenocarcinoma c.286C>T p.Q96* 16
19 COSM48840 VAV3 lung,NS,carcinoma,adenocarcinoma c.2519C>A p.S840Y 16
20 COSM48841 VAV3 lung,NS,carcinoma,adenocarcinoma c.1852C>G p.Q618E 16
21 COSM48838 VAV2 lung,NS,carcinoma,adenocarcinoma c.428G>T p.R143L 16
22 COSM48839 VAV2 lung,NS,carcinoma,adenocarcinoma c.301G>T p.D101Y 16
23 COSM48837 VAV1 lung,NS,carcinoma,adenocarcinoma c.2402T>C p.L801P 16
24 COSM95504 VAV1 lung,NS,carcinoma,adenocarcinoma c.1551C>A p.D517E 16
25 COSM48836 VAV1 lung,NS,carcinoma,adenocarcinoma c.175G>A p.E59K 16
26 COSM95743 USP4 lung,NS,carcinoma,adenocarcinoma c.2645-1G>C p.? 16
27 COSM95461 USP33 lung,NS,carcinoma,adenocarcinoma c.1151A>G p.D384G 16
28 COSM95460 USP33 lung,NS,carcinoma,adenocarcinoma c.1219A>G p.R407G 16
29 COSM95456 USP31 lung,NS,carcinoma,adenocarcinoma c.1681G>T p.D561Y 16
30 COSM96263 USP22 lung,NS,carcinoma,adenocarcinoma c.1399C>T p.L467L 16
31 COSM96261 USP20 lung,NS,carcinoma,adenocarcinoma c.477C>T p.A159A 16
32 COSM95684 USP19 lung,NS,carcinoma,adenocarcinoma c.1190C>G p.S397* 16
33 COSM94156 UBR5 lung,NS,carcinoma,adenocarcinoma c.3554G>T p.G1185V 16
34 COSM94157 UBR5 lung,NS,carcinoma,adenocarcinoma c.3368G>T p.G1123V 16
35 COSM94154 UBR5 lung,NS,carcinoma,adenocarcinoma c.4739G>T p.G1580V 16
36 COSM95839 UBR5 lung,NS,carcinoma,adenocarcinoma c.8328C>G p.L2776L 16
37 COSM48834 TYK2 lung,NS,carcinoma,adenocarcinoma c.3206C>G p.A1069G 16
38 COSM95422 TYK2 lung,NS,carcinoma,adenocarcinoma c.1181G>A p.S394N 16
39 COSM48833 TYK2 lung,NS,carcinoma,adenocarcinoma c.3545C>T p.S1182L 16
40 COSM95418 TTK lung,NS,carcinoma,adenocarcinoma c.2245G>T p.D749Y 16
41 COSM48830 TSHR lung,NS,carcinoma,adenocarcinoma c.1555C>A p.R519S 16
42 COSM48829 TSHR lung,NS,carcinoma,adenocarcinoma c.18G>T p.L6F 16
43 COSM48831 TSHR lung,NS,carcinoma,adenocarcinoma c.1966G>A p.V656I 16
44 COSM48826 TSC2 lung,NS,carcinoma,adenocarcinoma c.1414G>A p.V472M 16
45 COSM48827 TSC2 lung,NS,carcinoma,adenocarcinoma c.1923C>A p.S641R 16
46 COSM48828 TSC2 lung,NS,carcinoma,adenocarcinoma c.3867G>T p.R1289S 16
47 COSM48825 TSC1 lung,NS,carcinoma,adenocarcinoma c.611G>T p.R204L 16
48 COSM95412 TSC1 lung,NS,carcinoma,adenocarcinoma c.193C>G p.Q65E 16
49 COSM95403 TRIM33 lung,NS,carcinoma,adenocarcinoma c.1812G>T p.R604S 16
50 COSM95404 TRIM33 lung,NS,carcinoma,adenocarcinoma c.379G>A p.V127M 16

Copy number variations for Lung Cancer Susceptibility 3 from CNVD:

7 (show top 50) (show all 580)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13394 1 1 2300000 Gain Lung adenocarcinoma
2 13409 1 1 2300000 Gain Lung adenocarcinoma
3 13970 1 102000000 107000000 Loss Lung adenocarcinoma
4 13986 1 102200000 107200000 Loss Lung adenocarcinoma
5 14528 1 109314358 109386258 Deletion WDR47 Lung adenocarcinoma
6 15384 1 115048600 115061038 Copy number NRAS Lung adenocarcinoma
7 17560 1 143480000 149410000 Amplification ARNT Lung adenocarcinoma
8 18143 1 144218994 144222801 Amplification RBM8A Lung adenocarcinoma
9 18161 1 144227739 144235088 Amplification PEX11B Lung adenocarcinoma
10 18176 1 144287344 144297903 Amplification PIAS3 Lung adenocarcinoma
11 18223 1 144475951 145932379 Amplification GPR89A Lung adenocarcinoma
12 18385 1 145180914 145234067 Amplification CHD1L Lung adenocarcinoma
13 18405 1 145479805 145564639 Amplification BCL9 Lung adenocarcinoma
14 18433 1 145585791 145609258 Amplification ACP6 Lung adenocarcinoma
15 19003 1 148137824 148138969 Amplification BOLA1 Lung adenocarcinoma
16 19039 1 148305965 148384129 Amplification VPS45 Lung adenocarcinoma
17 19152 1 148885329 148936257 Amplification GOLPH3L Lung adenocarcinoma
18 19199 1 149165511 149203837 Amplification SETDB1 Lung adenocarcinoma
19 19207 1 149221122 149234738 Amplification ANXA9 Lung adenocarcinoma
20 19214 1 149247596 149274813 Amplification PRUNE Lung adenocarcinoma
21 19280 1 149399337 149404960 Amplification LYSMD1 Lung adenocarcinoma
22 19287 1 149415557 149429264 Amplification VPS72 Lung adenocarcinoma
23 19299 1 149493820 149506578 Amplification PSMD4 Lung adenocarcinoma
24 19341 1 149638664 149641036 Amplification PSMB4 Lung adenocarcinoma
25 19375 1 149998746 150002664 Amplification MRPL9 Lung adenocarcinoma
26 19378 1 150009206 150029634 Amplification TDRKH Lung adenocarcinoma
27 19432 1 150271605 150276135 Amplification S100A11 Lung adenocarcinoma
28 20047 1 152787674 152797744 Amplification UBE2Q1 Lung adenocarcinoma
29 20052 1 152821157 152867061 Amplification ADAR Lung adenocarcinoma
30 20569 1 153196125 153200882 Amplification PYGO2 Lung adenocarcinoma
31 20571 1 153201397 153213464 Amplification SHC1 Lung adenocarcinoma
32 20591 1 153213790 153218346 Amplification CKS1B Lung adenocarcinoma
33 20592 1 153222440 153232211 Amplification FLAD1 Lung adenocarcinoma
34 20617 1 153302836 153308653 Amplification EFNA4 Lung adenocarcinoma
35 20622 1 153317971 153326638 Amplification EFNA3 Lung adenocarcinoma
36 20838 1 154761820 154809020 Amplification IQGAP3 Lung adenocarcinoma
37 20853 1 154828181 154830715 Amplification APOA1BP Lung adenocarcinoma
38 20863 1 154936029 154941999 Amplification CRABP2 Lung adenocarcinoma
39 20868 1 154959036 154964835 Amplification ISG20L2 Lung adenocarcinoma
40 20872 1 154973717 154977547 Amplification MRPL24 Lung adenocarcinoma
41 20875 1 154978522 155003341 Amplification HDGF Lung adenocarcinoma
42 20983 1 155749790 155788934 Amplification FCRL5 Lung adenocarcinoma
43 21047 1 156490550 156494682 Amplification CD1A Lung adenocarcinoma
44 21335 1 158163454 158182010 Amplification IGSF9 Lung adenocarcinoma
45 21364 1 158264085 158268407 Amplification PIGM Lung adenocarcinoma
46 21422 1 158525000 158579978 Amplification COPA Lung adenocarcinoma
47 21516 1 159308119 159325966 Amplification PVRL4 Lung adenocarcinoma
48 21522 1 159336969 159354490 Amplification PFDN2 Lung adenocarcinoma
49 21527 1 159354514 159361857 Amplification NIT1 Lung adenocarcinoma
50 21533 1 159390157 159395270 Amplification UFC1 Lung adenocarcinoma

Expression for Lung Cancer Susceptibility 3

LifeMap Discovery
Genes differentially expressed in tissues of Lung Cancer Susceptibility 3 patients vs. healthy controls: 35 (show all 45)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1 TNNC1 troponin C type 1 (slow) Lung - 5.28 0.000
2 COL11A1 collagen, type XI, alpha 1 Lung + 5.07 0.000
3 MMP1 matrix metallopeptidase 1 Lung + 4.75 0.000
4 AGER advanced glycosylation end product-specific receptor Lung - 4.69 0.000
5 WIF1 WNT inhibitory factor 1 Lung - 4.60 0.000
6 SOSTDC1 sclerostin domain containing 1 Lung - 4.47 0.000
7 FABP4 fatty acid binding protein 4, adipocyte Lung - 4.32 0.000
8 CDH3 cadherin 3, type 1, P-cadherin (placental) Lung + 4.31 0.000
9 FOSB FBJ murine osteosarcoma viral oncogene homolog B Lung - 4.24 0.000
10 TMEM100 transmembrane protein 100 Lung - 4.20 0.000
11 CLEC3B C-type lectin domain family 3, member B Lung - 4.18 0.000
12 FCN3 ficolin (collagen/fibrinogen domain containing) 3 Lung - 4.17 0.000
13 MT1M metallothionein 1M Lung - 4.07 0.000
14 SPP1 secreted phosphoprotein 1 Lung + 4.04 0.000
15 SPINK1 serine peptidase inhibitor, Kazal type 1 Lung + 3.96 0.000
16 COL10A1 collagen, type X, alpha 1 Lung + 3.79 0.000
17 CLIC5 chloride intracellular channel 5 Lung - 3.65 0.000
18 ADIRF adipogenesis regulatory factor Lung - 3.65 0.000
19 RAMP2 receptor (G protein-coupled) activity modifying protein 2 Lung - 3.62 0.000
20 HIGD1B HIG1 hypoxia inducible domain family, member 1B Lung - 3.60 0.000
21 STXBP6 syntaxin binding protein 6 (amisyn) Lung - 3.59 0.000
22 TMPRSS4 transmembrane protease, serine 4 Lung + 3.53 0.000
23 EFCC1 EF-hand and coiled-coil domain containing 1 Lung - 3.47 0.000
24 MFAP4 microfibrillar-associated protein 4 Lung - 3.47 0.000
25 ABCC3 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 Lung + 3.47 0.000
26 TOP2A topoisomerase (DNA) II alpha Lung + 3.41 0.000
27 TCF21 transcription factor 21 Lung - 3.38 0.000
28 CA4 carbonic anhydrase IV Lung - 3.38 0.000
29 CYP4B1 cytochrome P450, family 4, subfamily B, polypeptide 1 Lung - 3.33 0.000
30 GPM6A glycoprotein M6A Lung - 3.30 0.000
31 GINS2 GINS complex subunit 2 (Psf2 homolog) Lung + 3.29 0.000
32 NEK2 NIMA-related kinase 2 Lung + 3.27 0.000
33 TOX3 TOX high mobility group box family member 3 Lung + 3.24 0.000
34 IL1RL1 interleukin 1 receptor-like 1 Lung - 3.21 0.000
35 PKNOX2 PBX/knotted 1 homeobox 2 Lung - 3.21 0.000
36 ABCA8 ATP-binding cassette, sub-family A (ABC1), member 8 Lung - 3.17 0.000
37 SCGB1A1 secretoglobin, family 1A, member 1 (uteroglobin) Lung - 3.17 0.000
38 FIGF c-fos induced growth factor (vascular endothelial growth factor D) Lung - 3.14 0.000
39 CRABP2 cellular retinoic acid binding protein 2 Lung + 3.11 0.000
40 SGCG sarcoglycan, gamma (35kDa dystrophin-associated glycoprotein) Lung - 3.10 0.000
41 ADAMTS8 ADAM metallopeptidase with thrombospondin type 1 motif, 8 Lung - 3.08 0.000
42 SFTPD surfactant protein D Lung - 3.07 0.000
43 MARCO macrophage receptor with collagenous structure Lung - 3.07 0.000
44 COL1A1 collagen, type I, alpha 1 Lung + 3.05 0.000
45 NMU neuromedin U Lung + 3.05 0.000
Search GEO for disease gene expression data for Lung Cancer Susceptibility 3.

Pathways for Lung Cancer Susceptibility 3

Pathways related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.55 EGFR ERBB2 HRAS KRAS KRT20 KRT7
2
Show member pathways
13.4 CASP3 EGFR ERBB2 HRAS KRAS MMP2
3
Show member pathways
13.32 CASP3 CDH1 EGFR ERBB2 HRAS KRAS
4
Show member pathways
13.02 CASP3 CDH1 HRAS KRAS TP53 VEGFA
5
Show member pathways
13.01 CDH1 EGFR ERBB2 HRAS KRAS MMP2
6
Show member pathways
12.83 CASP3 EGFR HRAS KRAS MMP2 VEGFA
7
Show member pathways
12.82 CASP3 CDH1 ERBB2 HRAS KRAS TP53
8
Show member pathways
12.76 EGFR ERBB2 HRAS KRAS TP53
9
Show member pathways
12.76 CDH1 EGFR HRAS KRAS RASSF1 VEGFA
10 12.75 CASP3 EGFR HRAS KRAS TP53
11
Show member pathways
12.7 CASP3 EGFR HRAS KRAS TP53
12 12.64 EGFR HRAS KRAS STK11 TP53 VEGFA
13
Show member pathways
12.63 EGFR ERBB2 HRAS KRAS MMP2 TP53
14
Show member pathways
12.54 EGFR ERBB2 HRAS KRAS STK11 TP53
15
Show member pathways
12.5 CASP3 CDH1 EGFR ERBB2 HRAS KRAS
16
Show member pathways
12.47 CASP3 EGFR ERBB2 HRAS KRAS TP53
17 12.45 CASP3 EGFR ERBB2 HRAS KRAS RASSF1
18
Show member pathways
12.39 EGFR HRAS KRAS VEGFA
19
Show member pathways
12.35 EGFR ERBB2 HRAS KRAS TP53
20
Show member pathways
12.33 CASP3 CDH1 EGFR ERBB2 HRAS KRAS
21 12.32 CASP3 HRAS KRAS TP53
22
Show member pathways
12.32 EGFR ERBB2 HRAS KRAS
23
Show member pathways
12.3 CASP3 HRAS KRAS TP53 VEGFA
24
Show member pathways
12.26 EGFR HRAS KRAS VEGFA
25 12.25 CASP3 CDH1 EGFR ERBB2 HRAS KRAS
26 12.22 EGFR ERBB2 HRAS KRAS
27
Show member pathways
12.22 CASP3 EGFR ERBB2 KRAS TP53
28
Show member pathways
12.18 CASP3 HRAS KRAS TP53
29
Show member pathways
12.17 EGFR ERBB2 HRAS KRAS
30
Show member pathways
12.17 HRAS KRAS STK11 TP53
31
Show member pathways
12.15 EGFR ERBB2 HRAS MMP2
32
Show member pathways
12.12 EGFR HRAS KRAS STK11
33
Show member pathways
12.1 EGFR ERBB2 HRAS KRAS
34 12.09 EGFR HRAS KRAS TP53
35
Show member pathways
12.08 EGFR ERBB2 HRAS KRAS TP53 VEGFA
36 12.08 CASP3 CDH1 EGFR KRAS MMP2 TP53
37 12.07 CASP3 EGFR ERBB2 HRAS KRAS MMP2
38 12.03 ERBB2 HRAS KRAS TP53
39 12.01 EGFR HRAS KRAS TP53
40 12 CDH1 CEACAM5 MMP2 MSLN
41
Show member pathways
11.99 EGFR ERBB2 HRAS KRAS
42 11.99 CASP3 CDH1 EGFR KRAS STK11 TP53
43 11.95 CASP3 HRAS KRAS MMP2 VEGFA
44
Show member pathways
11.83 CASP3 HRAS KRAS
45 11.77 CASP3 ERBB2 TP53
46 11.76 CDH1 EGFR ERBB2
47 11.73 CASP3 EGFR HRAS MMP2
48 11.72 CASP3 EGFR MMP2
49 11.72 ERBB2 HRAS TP53
50 11.7 HRAS KRAS TP53

GO Terms for Lung Cancer Susceptibility 3

Biological processes related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.88 CASP3 CEACAM5 EGFR OGG1 TP53 VEGFA
2 positive regulation of gene expression GO:0010628 9.8 ERBB2 HRAS KRAS NKX2-1 TP53 VEGFA
3 cell cycle arrest GO:0007050 9.73 HRAS RASSF1 STK11 TP53
4 Ras protein signal transduction GO:0007265 9.67 HRAS KRAS RASSF1 TP53
5 epidermal growth factor receptor signaling pathway GO:0007173 9.63 EGFR HRAS KRAS
6 positive regulation of epithelial cell proliferation GO:0050679 9.56 EGFR ERBB2 HRAS VEGFA
7 positive regulation of protein phosphorylation GO:0001934 9.55 EGFR ERBB2 HRAS KRAS VEGFA
8 cerebral cortex cell migration GO:0021795 9.51 EGFR NKX2-1
9 response to isolation stress GO:0035900 9.49 HRAS KRAS
10 surfactant homeostasis GO:0043129 9.48 NAPSA VEGFA
11 ERBB2 signaling pathway GO:0038128 9.26 EGFR ERBB2 HRAS KRAS
12 positive regulation of MAP kinase activity GO:0043406 9.02 EGFR ERBB2 HRAS KRAS VEGFA

Molecular functions related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 9.33 EGFR ERBB2 TP53
2 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 8.96 EGFR ERBB2
3 LRR domain binding GO:0030275 8.62 KRAS STK11

Sources for Lung Cancer Susceptibility 3

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....